Massive Subchorionic Haemorrhage: a Rare Case Report Associated with Secondary PPH Due to Uterine Artery Pseudoaneurysm
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Conclusion Report of 13Th National Perinatology Congress
Perinatal Journal 2011;19(1):35-50 e-Adress: http://www.perinataljournal.com/20110191009 doi:10.2399/prn.11.0191009 The Conclusion Report of 13th National Perinatology Congress Ayfle Kafkasl›1, Alper Tanr›verdi2, Yeflim Baytur3, Özlem Pata3, Ertan Adal›3, Hakan Camuzcuo¤lu3, Arif Güngören3, ‹lker Ar›kan3 1Head of the Congress, 13th National Perinatology Congress, ‹stanbul Türkiye 2Congress Secretary, 13th National Perinatology Congress, ‹stanbul Türkiye 3Congress Reporter, 13th National Perinatology Congress, ‹stanbul Türkiye The Conclusion Report of 13th The subject of “Fetal Postmortem Examination National Perinatology Congress and Chromosomal Analysis of Abortion Material” 13th National Perinatology Congress was held was presented by Dr. Gülay Ceylaner. According in ‹stanbul Military Museum and Culture Site in to the results of this presentation, postmortem between 13th and 16th April, 2011. examination should be performed on congenital anomalies, intrauterine growth retardation, non- Before the congress, 3 pre-congress courses immune hydrops fetalis, fetal-neonatal death histo- were held on 13th April, 2011. ry of unknown etiology or in fetuses with unknown death reason or maser (high frequency 1. Perinatal Genetic and Postmortem of chromosomal disorder). Findings should cer- Diagnosis Course tainly be recorded during examination, pho- In the first session, Assoc. Prof. Serdar Ceylaner tographs and X-ray should be taken and skin biop- made a presentation about “Basic Genetics and sy should be done. Fetus evaluation is really an Management of Genetic Diseases for the Clinician” easy and convenient examination method. and he explained that chromosomal analysis indi- In the presentation of “Fetal Autopsy: The cations are recurrent gestational losses, intrauterine Influence on Perinatal Mortality”, Prof. -
Unfavorable Progression of a Subchorionic Hematoma: a Case Report and Review of the Literature
GSC Biological and Pharmaceutical Sciences, 2020, 12(02), 074-079 Available online at GSC Online Press Directory GSC Biological and Pharmaceutical Sciences e-ISSN: 2581-3250, CODEN (USA): GBPSC2 Journal homepage: https://www.gsconlinepress.com/journals/gscbps (RESEARCH ARTICLE) Unfavorable progression of a subchorionic hematoma: A case report and review of the literature. Sofiane Kouas 1, *, Olfa Zoukar 2, Khouloud Ikridih 1, Sameh Mahdhi 1, Ichrak Belghaieb 1 and Anis Haddad 2 1Department of Gynecology and Obstetrics, Monastir Medical School, Monastir University, Gynecology-Obstetric Service Mahdia-Tunisia. 2 Department of Gynecology and Obstetrics, Monastir Medical School, Monastir University, El Omrane Hospital of Monastir-Monastir-Tunisia. Publication history: Received on 26 July 2020; revised on 06 August 2020; accepted on 09 August 2020 Article DOI: https://doi.org/10.30574/gscbps.2020.12.2.0242 Abstract A hematoma in the uterus or intrauterine hematoma is an effusion of blood that accumulates inside the uterine cavity during gestation. Hematomas, especially subchorionic hematomas, appear most often during the first trimester of pregnancy and can occur with or without vaginal bleeding. They are always a major cause for concern for pregnant women. We will consider pregnancy as a high risk pregnancy. It will then be necessary for the woman to keep rest and benefit from more exhaustive follow-up. This work, carried out from a case observed in our service and from a review of the literature, aims to highlight the existence of this entity and the possible unfavorable development with fetal and maternal risks. Keywords: Subchorionic hematoma; Ultrasound; Bleeding; Possible unfavorable course 1. -
A Guide to Obstetrical Coding Production of This Document Is Made Possible by Financial Contributions from Health Canada and Provincial and Territorial Governments
ICD-10-CA | CCI A Guide to Obstetrical Coding Production of this document is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government. Unless otherwise indicated, this product uses data provided by Canada’s provinces and territories. All rights reserved. The contents of this publication may be reproduced unaltered, in whole or in part and by any means, solely for non-commercial purposes, provided that the Canadian Institute for Health Information is properly and fully acknowledged as the copyright owner. Any reproduction or use of this publication or its contents for any commercial purpose requires the prior written authorization of the Canadian Institute for Health Information. Reproduction or use that suggests endorsement by, or affiliation with, the Canadian Institute for Health Information is prohibited. For permission or information, please contact CIHI: Canadian Institute for Health Information 495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6 Phone: 613-241-7860 Fax: 613-241-8120 www.cihi.ca [email protected] © 2018 Canadian Institute for Health Information Cette publication est aussi disponible en français sous le titre Guide de codification des données en obstétrique. Table of contents About CIHI ................................................................................................................................. 6 Chapter 1: Introduction .............................................................................................................. -
Drug Use and Pregnancy
Rochester Institute of Technology RIT Scholar Works Theses 7-28-1999 Drug use and pregnancy Kimberly Klapmust Follow this and additional works at: https://scholarworks.rit.edu/theses Recommended Citation Klapmust, Kimberly, "Drug use and pregnancy" (1999). Thesis. Rochester Institute of Technology. Accessed from This Thesis is brought to you for free and open access by RIT Scholar Works. It has been accepted for inclusion in Theses by an authorized administrator of RIT Scholar Works. For more information, please contact [email protected]. ROCHESTER INSTITUTE OF TECHNOLOGY A Thesis Submitted to the Faculty of The College of Imaging Arts and Sciences In Candidacy for the Degree of MASTER OF FINE ARTS Drug Use and Pregnancy by Kimberly A. Klapmust July 28, 1999 Approvals Adviser: Robert Wabnitz Date: Associate Adviser. Dr. Nancy Wanek ~)14 Date: \\.\,, c Associate Advisor: Glen Hintz Date ]I-I, zJ Cf9 I 7 Department ChaiIWrson: _ Dale: 1//17._/c; '1 I, , hereby deny permission to the Wallace Memorial library of RIT to reproduce my thesis in whole or in part. Any reproduction will not be for commercial use or profit. INTRODUCTION Human development is a remarkably complex process whereby the union of two small cells can after a period of time give rise to a new human being, complete with vital organs, bones, muscles, nerves, blood vessels, and much more. Considering the intricacy of the developmental process, it is indeed miraculous that most babies are born healthy. Some children, however, are born with abnormalities. Environmental agents, such as drugs, are responsible for some of these abnormalities. -
1. State That Your Patient Is Pregnant Or Postpartum. the Pregnancy 2
Louisiana Guidelines for Drafting Work Accommodation Notes for Pregnant and Postpartum Patients *These guidelines apply only in Louisiana. Visit the Pregnant@Work website (www.pregnantatwork.org) for other states. ACOG’s Committee Opinion on Employment Considerations (#733) recommends that obstetric care providers assist their patients to obtain accommodations by writing appropriate notes to employers following these state-specific guidelines. Attached as Appendix A is a sample work note that maximizes the likelihood that your patient will receive the accommodation she needs to continue working. Louisiana law1 requires employers with 25 or more employees: • To temporarily transfer a pregnant employee to a less strenuous or hazardous position based on the advice of her physician, where a position exists and is open, and where the pregnant woman is qualified to perform the job. • To provide leave to a woman who is disabled on account of pregnancy, childbirth, or a related medical condition, during the period of her disability, but for no more than 4 months. Federal and state law may also require employers to provide a pregnant woman accommodations other than transfer or leave, so she can continue working safely. Health care providers can play an important role in enabling patients to receive the accommodations they need to keep their jobs during pregnancy and following childbirth. In most cases, the goal is to write a note that will assist your patient to receive the accommodation she needs to continue working and earning an income for the family she supports. Before you recommend that a pregnant patient take leave or adopt a reduced schedule, see “Caution: Recommending leave” under #6 below. -
The Law of Placenta
The Law of Placenta Mathilde Cohent ABSTRACT: Of the forms of reproductive labor in which legal scholars have been interested, placenta, the organ developed during pregnancy, has been overlooked. As placenta becomes an object of value for a growing number of individuals, researchers, clinicians, biobanks, and biotech companies, among others, its cultural meaning is changing. At the same time, these various constituencies may be at odds. Some postpartum parents and their families want to repossess their placenta for personal use, while third parties use placentas for a variety of research, medical, and commercial purposes. This Article contributes to the scholarship on reproductive justice and agency by asking who should have access to placentas and under what conditions. The Article emphasizes the insufficient protection the law affords pregnant people wishing to decide what happens to their placenta. Generally considered clinical waste under federal and state law, placental tissue is sometimes made inaccessible to its producers on the ground that it is infectious at the same time as it is made available to third parties on the ground that placenta is discarded and de-identified tissue. Less privileged people who lack the ability to shop for obstetric and other pregnancy-related services that allow them to keep their placentas are at a disadvantage in this chain of supply and demand. While calling for further research on the modus operandi of placenta markets and how pregnant people think about them, this Article concludes that lawmakers should take steps to protect decision-making autonomy over placental labor and offers a range of proposals to operationalize this idea. -
Role of Ultrasound in the Evaluation of First-Trimester Pregnancies in the Acute Setting
University of Massachusetts Medical School eScholarship@UMMS Radiology Publications Radiology 2020-04-01 Role of ultrasound in the evaluation of first-trimester pregnancies in the acute setting Venkatesh A. Murugan University of Massachusetts Medical School Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/radiology_pubs Part of the Female Urogenital Diseases and Pregnancy Complications Commons, Obstetrics and Gynecology Commons, Radiology Commons, and the Women's Health Commons Repository Citation Murugan VA, Murphy BO, Dupuis CS, Goldstein AJ, Kim YH. (2020). Role of ultrasound in the evaluation of first-trimester pregnancies in the acute setting. Radiology Publications. https://doi.org/10.14366/ usg.19043. Retrieved from https://escholarship.umassmed.edu/radiology_pubs/526 Creative Commons License This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Radiology Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. Role of ultrasound in the evaluation of first-trimester pregnancies in the acute setting Venkatesh A. Murugan, Bryan O’Sullivan Murphy, Carolyn Dupuis, Alan Goldstein, Young H. Kim PICTORIAL ESSAY Department of Radiology, University of Massachusetts Medical School, Worcester, MA, USA https://doi.org/10.14366/usg.19043 pISSN: 2288-5919 • eISSN: 2288-5943 Ultrasonography 2020;39:178-189 In patients presenting for an evaluation of pregnancy in the first trimester, transvaginal ultrasound is the modality of choice for establishing the presence of an intrauterine pregnancy; evaluating pregnancy viability, gestational age, and multiplicity; detecting pregnancy-related Received: July 25, 2019 complications; and diagnosing ectopic pregnancy. -
Ultrasound in Prediction of Threatened Abortion in Early Pregnancy: a Clinical Study
International Journal of Medical Arts 2020; 2 [2]: 451-456. Available online at Journal Website https://ijma.journals.ekb.eg/ Main subject [Medicine [Obstetrics]] * Original article Ultrasound in Prediction of Threatened Abortion in Early Pregnancy: A clinical study Shimaa Shaker Zeed Saleha; Khattab Abd El-halim Omar Khattabb; Ehab Mohammed Elhelwb Department of Obstetrics and Gynecology, Damietta Specialized Hospital, Ministry of Health, Egypt[a]. Department of Obstetrics and Gynecology, Damietta Faculty of Medicine, Al-Azhar University, Egypt[b]. Corresponding author: Shimaa Shaker Zeed Saleh Email: a [email protected] Submitted at: September 25, 2019; Revised at: April 14, 2020; Accepted at: April 15, 2020; Available online at: April 15, 2020 DOI: 10.21608/ijma.2020.17353.1032 ABSTRACT Background: Early pregnancy loss is a challenging health problem and the prediction of exposed females is mandatory to permit early intervention and prevention. Aim of the work: To assess utility of ultrasound in detection of threatened abortion in early pregnancy. Patients and Methods: One-hundred females with history of threatened abortion were included. A written consent was obtained from each participant. Patients were divided into two groups: Group [I]: 85 Cases who continued their pregnancy. Group [II]: 15 Cases ended by abortion. All females were submitted to: detailed history, clinical examination [General and abdominal] and investigations in the form of ultrasound. Data were collected and statistically analyze. Results: 15% of studied females had early miscarriage. There was a significant relation between occurrence of abortion and gestational age as abortion was more frequent with reduced gestational age. In addition, high parity [P1-2] was significantly associated with abortion. -
Amniocentesis.Pdf
Amniocentesis Introduction Amniocentesis is a diagnostic test carried out during pregnancy. It can assess whether the unborn baby (foetus) could develop, or has developed, an abnormality or serious health condition. Things that increase the risk of an abnormality include: ● the mother's age ● the mother's medical history ● a family history of inherited genetic conditions Why and when amniocentesis is used Amniocentesis can be used to detect a number of conditions, such as: ● Down's syndrome – a genetic condition that affects a person's physical appearance and mental development ● spina bifida – a series of birth defects that affect the development of the spine and nervous system ● sickle cell anaemia – a genetic disorder that causes a person's red blood cells to develop abnormally Read more about why amniocentesis is used. Amniocentesis is usually carried out during weeks 15-20 of the pregnancy. The procedure can be performed earlier than 15 weeks, but this is avoided if possible because it may increase the risk of causing complications or a miscarriage (loss of the pregnancy). Read more about when amniocentesis is used. What happens during amniocentesis NHS Choices puts you in control of your healthcare NHS Choices has been developed to help you make choices about your health, from lifestyle decisions about things like smoking, drinking and exercise, through to the practical aspects of finding and using NHS services when you need them. www.nhs.uk Before you have amniocentesis, a healthcare professional will explain the procedure to you, including why they think it's necessary and the benefits and risks. They'll also tell you about any alternative tests that may be appropriate, such as chorionic villus sampling (CVS). -
Management of PRELABOUR RUPTURE of MEMBRANES at Term May 2014 CLINICAL PRACTICE GUIDELINE NO.13 Management of Prelabour Rupture of Membranes at Term
CLINICAL PRACTICE GUIDELINE13 Management of PRELABOUR RUPTURE OF MEMBRANES at term May 2014 CLINICAL PRACTICE GUIDELINE NO.13 Management of prelabour rupture of Membranes at term AUTHORS CONTRIBUTORS Tasha MacDonald, RM, MHSc Suzannah Bennett, MHSc Kathleen Saurette, RM Cindy Hutchinson, MSc Bobbi Soderstrom, RM CONTRIBUTORS ACKNOWLEDGEMENTS PROM CPG Working Group Megan Bobier, BA Clinical Practice Guideline Subcommittee Ontario Ministry of Health and Long-term Care Teresa Bandrowska, RM Ryerson University Midwifery Education Program Cheryllee Bourgeois, RM Elizabeth Darling, RM , MSc The Association of Ontario Midwives respectfully Corinne Hare, RM acknowledges the financial support of the Ministry of Sandy Knight, RM Health and Long-Term Care in the development of this Jenni Huntly, RM guideline. Paula Salehi, RM The views expressed in this guideline are strictly those Lynlee Spencer, RM of the Association of Ontario Midwives. No official Vicki Van Wagner, RM, PhD (c) endorsement by the Ministry of Health and Long-Term Rhea Wilson, RM Care is intended or should be inferred. Insurance and Risk Management Program ‘Remi Ejiwunmi, RM, Chair Abigail Corbin, RM Elana Johnston, RM Lisa M Weston, RM This document may be cited as: PROM CPG Working Group. Association of Ontario Midwives. Management of Prelabour Rupture of Membranes at Term. July 2010. This guideline was approved by the AOM Board of Directors: July 5, 2010 Management of PRELABOUR RUPTURE OF MEMBRANES at term Statement of purpose Methods The goal is to provide an evidence-based clinical practice A search of the Medline database and Cochrane library guideline (CPG) that is consistent with the midwifery from 1994-2009 was conducted using the key words: philosophy of care. -
Aplastic Anemia During Pregnancy Open Access to Scientific and Medical Research DOI: 149683
Journal name: International Journal of Women’s Health Article Designation: Review Year: 2018 Volume: 10 International Journal of Women’s Health Dovepress Running head verso: Riveros-Perez et al Running head recto: Aplastic anemia during pregnancy open access to scientific and medical research DOI: 149683 Open Access Full Text Article REVIEW Aplastic anemia during pregnancy: a review of obstetric and anesthetic considerations Efrain Riveros-Perez1 Abstract: Aplastic anemia is a hematologic condition occasionally presenting during pregnancy. Amy C Hermesch2 This pathological process is associated with significant maternal and neonatal morbidity and Linda A Barbour3 mortality. Obstetric and anesthetic management is challenging, and treatment requires a Joy L Hawkins4 coordinated effort by an interdisciplinary team, in order to provide safe care to these patients. In this review, we describe the current state of the literature as it applies to the complexity of 1Department of Anesthesiology and Perioperative Medicine, Medical aplastic anemia in pregnancy, focusing on pathophysiologic aspects of the disease in pregnancy, College of Georgia, Augusta as well as relevant obstetric and anesthetic considerations necessary to treat this challenging 2 University, Augusta, GA, Maternal problem. A multidisciplinary-team approach to the management of aplastic anemia in pregnancy Fetal Medicine, 3Obstetrics and Gynecology, 4Department of is necessary to coordinate prenatal care, optimize maternofetal outcomes, and plan peripartum Anesthesiology, University of interventions. Conservative transfusion management is critical to prevent alloimmunization. Colorado School of Medicine, Although a safe threshold-platelet count for neuraxial anesthesia has not been established, Aurora, CO, USA For personal use only. selection of anesthetic technique must be evaluated on a case-to-case basis. -
NONINVASIVE PRENATAL TESTING: INFORMATION for PHYSICIANS Illinois Department of Public Health
NONINVASIVE PRENATAL TESTING: INFORMATION FOR PHYSICIANS Illinois Department of Public Health DEFINITION Noninvasive prenatal testing (NIPT) examines fetal DNA within the mother’s blood and is a screening method for detecting chromosome abnormalities in a developing fetus. NIPT screens for trisomy 21 (Down syndrome), as well as two other less common chromosome abnormalities, trisomy 13, and trisomy 18. This blood test can also screen for sex chromosome abnormalities and the fetus’s Rh factor. HOW IS NIPT PERFORMED? At ten weeks gestation, a blood sample is taken from the mother and sent to a reproductive testing laboratory for analysis. The laboratory compares the mother’s DNA with the fetus’s DNA and examines the chromosomes present. A higher than normal percentage of chromosomes may suggest a chromosome abnormality. WHEN IS NIPT RECOMMENDED? Currently, this testing is routinely offered to women with certain characteristics such as: Advanced maternal age (35 years and older) A woman who has previously given birth to a baby with trisomy 21, trisomy 18, or trisomy 13 A woman who is carrier of an X-linked recessive disorder An abnormal serum screen A family history of chromosome abnormalities An abnormal prenatal ultrasound HOW DOES NIPT COMPARE TO AMNIOCENTESIS AND CHORIONIC VILLUS SAMPLING? Currently, NIPT is the only one of these 3 tests offered to pregnant woman that poses no physical risks to the mother or fetus. An amniocentesis and chorionic villus sampling (CVS) are both invasive prenatal tests that carry a risk for miscarriage. The risk for a miscarriage with an amniocentesis is 0.1%, whereas the risk for a miscarriage with CVS is 0.2%.